Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The interaction between donor Human Leukocyte Antigen (HLA) molecules and recipient T-cell receptors (TCR) is the fundamental immunological event in solid organ transplantation and hematopoietic stem cell transfer (Source: Murphy K, Weaver C. Janeway's Immunobiology. 9th ed. Garland Science; 2016). HLA molecules, also known as Major Histocompatibility Complex (MHC) proteins, are expressed on the surface of donor cells and present peptides to the recipient's T-cells (Source: NIH, National Institute of Allergy and Infectious Diseases). When the recipient's TCR recognizes the donor HLA-peptide complex as non-self—a process known as allorecognition—it triggers a robust immune response (Source: Ingulli E. Mechanism of cellular rejection in transplantation. Pediatr Nephrol. 2010;25(1):61-74). This response leads to T-cell proliferation, cytokine production, and the eventual destruction of the transplanted tissue, manifesting as graft rejection (Source: Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med. 2010;363(15):1451-62). Conversely, in bone marrow transplants, donor T-cells may recognize recipient HLA, resulting in graft-versus-host disease (Source: Zeiser R, Blazar BR. Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med. 2017;377(22):2167-2179). Therapeutic strategies targeting this interaction include broad immunosuppressants that inhibit downstream TCR signaling, such as calcineurin inhibitors, and more specific biologics like belatacept that block necessary costimulatory signals (Source: Vincenti F, et al. Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med. 2016;374:333-343).
Inhibition of calcineurin-mediated T-cell activation, blockade of CD80/CD86-CD28 costimulation, depletion of T-lymphocytes, and inhibition of IL-2 receptor signaling.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Donor Human Leukocyte Antigen (HLA) and Recipient T-cell Receptor (TCR) Complex (HLA-TCR Complex).